Spero Therapeutics Inc’s recent filing unveils that its CFO & CBO Rajavelu Esther unloaded Company’s shares for reported $30590.0 on Nov 07 ’24. In the deal valued at $1.31 per share,23,351 shares were sold. As a result of this transaction, Rajavelu Esther now holds 396,515 shares worth roughly $0.36 million.
Then, Rajavelu Esther sold 17,245 shares, generating $22,418 in total proceeds. Upon selling the shares at $1.30, the CFO & CBO now owns 379,270 shares.
Before that, Mahadevia Ankit sold 5,912 shares. Spero Therapeutics Inc shares valued at $7,981 were divested by the Director at a price of $1.35 per share. As a result of the transaction, Mahadevia Ankit now holds 759,085 shares, worth roughly $0.69 million.
Evercore ISI downgraded its Spero Therapeutics Inc [SPRO] rating to an In-line from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who increased its forecast for the stock in late September from “an In-line” to “an Outperform”. Oppenheimer also remained covering SPRO and has decreased its forecast on October 01, 2021 with a “Perform” recommendation from previously “an Outperform” rating. H.C. Wainwright maintained its rating on January 22, 2021. It rated SPRO as “a Buy”.
Price Performance Review of SPRO
On Friday, Spero Therapeutics Inc [NASDAQ:SPRO] saw its stock jump 9.00% to $0.91. Over the last five days, the stock has lost -7.14%. Spero Therapeutics Inc shares have fallen nearly -11.65% since the year began. Nevertheless, the stocks have fallen -36.81% over the past one year. While a 52-week high of $1.89 was reached on 01/06/25, a 52-week low of $0.83 was recorded on 01/16/25. SMA at 50 days reached $1.1049, while 200 days put it at $1.3208.
Levels Of Support And Resistance For SPRO Stock
The 24-hour chart illustrates a support level at 0.8577, which if violated will result in even more drops to 0.8053. On the upside, there is a resistance level at 0.9512. A further resistance level may holdings at 0.9923. The Relative Strength Index (RSI) on the 14-day chart is 38.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1147, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 73.33%. Stochastics %K at 12.90% indicates the stock is a buying.
How much short interest is there in Spero Therapeutics Inc?
A steep rise in short interest was recorded in Spero Therapeutics Inc stocks on 2024-10-31, growing by 0.24 million shares to a total of 0.63 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.38 million shares. There was a rise of 38.53%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 16, 2020 when Berenberg began covering the stock and recommended ‘”a Buy”‘ rating along with a $47 price target.
